WYETH for WYETH
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement Importation of FDA-approved pharmaceuticals
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| BRONWEN KAYE | — |
| JULIE RABINOWITZ | — |
Taxation/Internal Revenue Code TAX
Taxation of International Operations of U.S. corporations generally; Homeland investment legislation; R&D tax credit; repatriation of foreign source income; deferral of U.S. taxation of foreign source income
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| JULIE RABINOWITZ | — |
Copyright/Patent/Trademark CPT
Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement health care reform legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| BRONWEN KAYE | — |
| JULIE RABINOWITZ | — |
Health Issues HCR
Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; Childhood immunizations Dietary supplement issues Alzheimer's care Pediatric Studies and Trials Drug Safety/Clinical Trials Health care issues Health care reform legislation Drug approvals Reimbursement rates FDA Pre-emption Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Chronic care out of pocket costs Vaccine Program H.R. 1427 - Access to Life-Saving Medicine Act H.R. 1548 - The Pathway for Biosimilars Act Legislative and regulatory issues related to hormone replacement therapies International public health issues International vaccine issues H.R. 1/S350 - The American Recovery and Reinvestment Act of 2009 H.R. 579 - The Food and Drug Administration Globalization Act S. 525/H.R. 1298 - The Pharmaceutical Market Access and Drug Safety Act of 2009 S. 301 - Physican Payments Sunshine Act of 2009 H.R. 573 - Authorized Generics S. 501 - Fair Prescription Drug Competition Act S. 369 - Preserve Access to Affordable Generics Act H.R. 1706 - Protecting consumer Access to Generic Drugs Act S.357 - Sunshine in Litigation Act of 2009 H.R. 3200 - American's Affordable Health Choices Act of 2009 S. ___ Affordable Health Choices Act S.1213 - Patient Centered Outcomes Research Act of 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| BRONWEN KAYE | — |
| JULIE RABINOWITZ | — |
| ANGELA WALKER RIEMER | — |
Medicare/Medicaid MMM
Vaccines Medicare chronic disease coverage Implementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003 Medicare coverage of pharmaceuticals, Medicare Part D Chronic care out of pocket costs Medicare Prescription Drug Benefit Medicaid drug rebate Medicare and Medicaid Drug Reimbursement Medicaid Part D Non-Interference S.301 Physician Payments Sunshine Act of 2009 S.547/H.R. 904 - Drug Rebate Equalization Act of 2009 H.R. 1725 - Voluntary State Discount Prescription Drug Plan Act of 2009 S.330/H.R. 684 - Medicare Prescription Drug Savings and Choice Act of 2009 S.266 - Medicare Prescription Drug Gap Reduction Act of 2009 H.R. ____ - House Tri-Committee Health Reform S.____ Affordable Health Choices Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| BRONWEN KAYE | — |
| JULIE RABINOWITZ | — |
| ANGELA WALKER RIEMER | — |
Consumer Issues/Safety/Products CSP
FDA reform proposals; Pseudoephedrine H.R. 1259 DXM Distribution Act Monograph System Reform Proposal Pseudoephedrine Electronic Log Proposal S.1383 Dextromethorphan Abuse Reduction Act of 2009 H.R. 2749 Food Safety Enhancement Act of 2009 S. 510 Food Safety Modernization Act of 2009
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| BRONWEN KAYE | — |
| JULIE RABINOWITZ | — |
| ANGELA WALKER RIEMER | — |
Pharmacy PHA
S. 726/H.R. 1427 - Access to Life-Saving Medicine Act, Follow-on Biologics H.R. 1548 - The Pathway for Biosimilars Act Biosimilars Drug Safety Prescription Drug Importation Import Safety Compounding H.R. 759 - Food and Drug Administration Globaliation Act of 2009 S. 510 - FDA Food Safety Modernization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO C JARDOT | — |
| BRONWEN KAYE | — |
| JULIE RABINOWITZ | — |
| ANGELA WALKER RIEMER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.